कनाडा -
अंग्रेज़ी -
Health Canada
taro-sunitinib capsule
taro pharmaceuticals inc - sunitinib (sunitinib malate) - capsule - 37.5mg - sunitinib (sunitinib malate) 37.5mg
कनाडा -
अंग्रेज़ी -
Health Canada
taro-sunitinib capsule
taro pharmaceuticals inc - sunitinib (sunitinib malate) - capsule - 12.5mg - sunitinib (sunitinib malate) 12.5mg
कनाडा -
अंग्रेज़ी -
Health Canada
taro-sunitinib capsule
taro pharmaceuticals inc - sunitinib (sunitinib malate) - capsule - 25mg - sunitinib (sunitinib malate) 25mg
कनाडा -
अंग्रेज़ी -
Health Canada
taro-sunitinib capsule
taro pharmaceuticals inc - sunitinib (sunitinib malate) - capsule - 50mg - sunitinib (sunitinib malate) 50mg
कनाडा -
अंग्रेज़ी -
Health Canada
auro-sunitinib capsule
auro pharma inc - sunitinib (sunitinib malate) - capsule - 12.5mg - sunitinib (sunitinib malate) 12.5mg
कनाडा -
अंग्रेज़ी -
Health Canada
auro-sunitinib capsule
auro pharma inc - sunitinib (sunitinib malate) - capsule - 25mg - sunitinib (sunitinib malate) 25mg
कनाडा -
अंग्रेज़ी -
Health Canada
auro-sunitinib capsule
auro pharma inc - sunitinib (sunitinib malate) - capsule - 37.5mg - sunitinib (sunitinib malate) 37.5mg
कनाडा -
अंग्रेज़ी -
Health Canada
auro-sunitinib capsule
auro pharma inc - sunitinib (sunitinib malate) - capsule - 50mg - sunitinib (sunitinib malate) 50mg
इसराइल -
अंग्रेज़ी -
Ministry of Health
sutent 12.5 mg
pfizer pharmaceuticals israel ltd - sunitinib as malate - capsules - sunitinib as malate 12.5 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.
इसराइल -
अंग्रेज़ी -
Ministry of Health
sutent 25 mg
pfizer pharmaceuticals israel ltd - sunitinib as malate - capsules - sunitinib as malate 25 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.